Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Shanghai Henlius Biotech
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07459738CT.gov A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Tumor Luminal A Or B
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hlx43 (this asset) | Shanghai Henlius Biotech | P2 | CCC · 53 |
| Letrozole | BeOne Medicines | P4 | BB |
| Fulvestrant | BeiGene | P2/3 | B |
| Elacestrant | GBG Forschungs GmbH | P2 | B |
| Cyclophosphamide | Puma Biotechnology, Inc. | P3 | B |
| Carboplatin | Fudan University | P3 | B |
| Epirubicin | Fudan University | P3 | B |
| Palbociclib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P2/3 | B |
| Azacitidine | University Health Network, Toronto | P2 | B |
+16 more in the Breast Tumor Luminal A Or B cohort
Other indications for hlx43
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Squamous Lung Carcinoma | — | P2/3 | B · 57 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 53 |
| Hepatocellular Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hlx43 in Breast Tumor Luminal A Or B. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hlx43-breast-tumor-luminal-a-or-b
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →